Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of pulmonary fibrosis in people with underlying lung ...

Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...

Columnist Sam Kirton shares his thoughts on recent CDC vaccine recommendations, as well as his experience before and after transplant.

The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...

My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, ...

GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. “The FVC data after 6 weeks ...

Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...